The Approvals include CONFIENT™ ICD, LIVIAN™ CRT-D and upgraded LATITUDE® Patient Management System

Boston Scientific Corporation has today announced that it received U.S. Food and Drug Administration (FDA) approval for three products in its Cardiac Rhythm Management business. They are:

  -- The CONFIENT™ implantable cardioverter defibrillator (ICD), which  helps protect patients at risk of sudden cardiac death

  -- The LIVIAN™ cardiac resynchronization therapy defibrillator (CRT-D), which provides cardiac resynchronization and defibrillation therapies in one device

  --  An upgraded LATITUDE® Patient Management System, with enhanced remote monitoring capabilities

 Jim Tobin, President and Chief Executive Officer of Boston Scientific said that their Cardiac Rhythm Management (CRM) team is refocused on delivering therapy systems that meet physicians needs for safety, reliability and better patient outcomes.These and other recent approvals are tangible examples of the team's revitalized commitment to quality and innovation.